Pre-Activity Questions

Currently, how confident are you in your ability: *

Please use the scale: 1=NOT at all confident, 2=Somewhat confident, 3=Confident, 4=Very confident, 5=EXTREMELY confident, N/A=Not within the scope of my practice

	1	2	3	4	5	N/A
in applying current evidence-based guidelines for the diagnosis and management of patients with IPF?	in applying current evidence-based guidelines for the diagnosis and management of patients with IPF? - 1	in applying current evidence-based guidelines for the diagnosis and management of patients with IPF? - 2	in applying current evidence-based guidelines for the diagnosis and management of patients with IPF? - 3	in applying current evidence-based guidelines for the diagnosis and management of patients with IPF? - 4	in applying current evidence-based guidelines for the diagnosis and management of patients with IPF? - 5	in applying current evidence-based guidelines for the diagnosis and management of patients with IPF? - N/A
to incorporate clinical trial data into personalized treatment strategies for patients with IPF?	to incorporate clinical trial data into personalized treatment strategies for patients with IPF? - 1	to incorporate clinical trial data into personalized treatment strategies for patients with IPF? - 2	to incorporate clinical trial data into personalized treatment strategies for patients with IPF? - 3	to incorporate clinical trial data into personalized treatment strategies for patients with IPF? - 4	to incorporate clinical trial data into personalized treatment strategies for patients with IPF? - 5	to incorporate clinical trial data into personalized treatment strategies for patients with IPF? - N/A

The FDA as a treatment option has approved pirfenidone for IPF. This therapy has shown a significant decrease in the rate of decline in which of the following metrics? *

Inspiratory Vital Capacity

Forced Vital Capacity

Expiratory Vital Capacity

Functional Residual Capacity

You are developing a treatment plan for a 60-year old patient with a history of cardiovascular disease. Which therapeutic options would be most appropriate for this patient? *

Pirfenidone

Nintedanib

Both therapies would be appropriate

Neither therapy would be appropriate

You are developing a treatment plan for a 55-year old patient with IPF who works as a landscaper and spends most of his day out in the sun. Which of the following therapeutic options would be most appropriate for this patient? *

Pirfenidone

Nintedanib

Both therapies would be appropriate

Neither therapy would be appropriate

True or False: Research presented at ATS 2015 from National Jewish Health and University of Chicago showed connective tissue–associated usual interstitial pneumonia (UIP) and idiopathic UIP are markedly different. *

True

False

Researchers at University of Cincinnati College of Medicine presented data on a study observing the gene expression changes that occur when epithelial cells differentiate from type 1 to type 2. This differentiation process is important in terms of lung repair. Results displayed _____ showed mixed patterns of gene expression, which inhibits their normal differentiation process? *

Type 1 cells

Type 2 cells

Type 1 and type 2 cells

Neither type 1 or type 2 cells

Pulmonary hypertension would be a major safety concern for which of the following diagnostic measures when evaluating a patient with suspected IPF? *

HRCT

Serological testing

Transbronchial biopsy

None of the above

Please indicate how often you CURRENTLY use each of the following practice strategies for your patients with IPF. You will not be graded on your responses. *

Please use the scale: 1=Never, 2=Not often, 3=Sometimes, 4=Often, 5=Always, N/A=Not applicable to me

	1	2	3	4	5	N/A
Utilize a multidisciplinary approach between pulmonologists, radiologists, and pathologists when evaluating suspected IPF	Utilize a multidisciplinary approach between pulmonologists, radiologists, and pathologists when evaluating suspected IPF - 1	Utilize a multidisciplinary approach between pulmonologists, radiologists, and pathologists when evaluating suspected IPF - 2	Utilize a multidisciplinary approach between pulmonologists, radiologists, and pathologists when evaluating suspected IPF - 3	Utilize a multidisciplinary approach between pulmonologists, radiologists, and pathologists when evaluating suspected IPF - 4	Utilize a multidisciplinary approach between pulmonologists, radiologists, and pathologists when evaluating suspected IPF - 5	Utilize a multidisciplinary approach between pulmonologists, radiologists, and pathologists when evaluating suspected IPF - N/A
Provide accurate information on all therapeutic options when discussing treatment plans with your patients with IPF	Provide accurate information on all therapeutic options when discussing treatment plans with your patients with IPF - 1	Provide accurate information on all therapeutic options when discussing treatment plans with your patients with IPF - 2	Provide accurate information on all therapeutic options when discussing treatment plans with your patients with IPF - 3	Provide accurate information on all therapeutic options when discussing treatment plans with your patients with IPF - 4	Provide accurate information on all therapeutic options when discussing treatment plans with your patients with IPF - 5	Provide accurate information on all therapeutic options when discussing treatment plans with your patients with IPF - N/A
Regularly identify microaspiration associated with gastroesophageal reflux as a risk factor for IPF	Regularly identify microaspiration associated with gastroesophageal reflux as a risk factor for IPF - 1	Regularly identify microaspiration associated with gastroesophageal reflux as a risk factor for IPF - 2	Regularly identify microaspiration associated with gastroesophageal reflux as a risk factor for IPF - 3	Regularly identify microaspiration associated with gastroesophageal reflux as a risk factor for IPF - 4	Regularly identify microaspiration associated with gastroesophageal reflux as a risk factor for IPF - 5	Regularly identify microaspiration associated with gastroesophageal reflux as a risk factor for IPF - N/A

Leave this field blank

You are here